Suppr超能文献

[定量评分系统在上消化道黏膜变化测定中的应用。双氯芬酸泡腾片与传统双氯芬酸制剂及阿司匹林重复给药后的比较研究]

[Application of quantifying scoring systems for the determination of changes in the mucosa of the upper gastrointestinal tract. A comparative study of a diclofenac effervescent tablet with conventional diclofenac preparations and acetylsalicylic acid after repeated administration].

作者信息

Wildgrube Hans Jörg, Kierschke Gerd, Nowak Horst, Weigmann Ingo, Terhaag Bernd

机构信息

Institute for Applied Diagnostic International (IAD International Ltd.), Mahone Bay, Nova Scotia, Canada.

出版信息

Arzneimittelforschung. 2002;52(4):264-72. doi: 10.1055/s-0031-1299890.

Abstract

UNLABELLED

Application of Quantifying Scoring Systems for the Determination of Changes of the Mucosa of the Upper Gastrointestinal Tract/A comparative study of a diclofenac effervescent tablet with conventional diclofenac preparations and acetylsalicylic acid after repeated administration.

BACKGROUND AND AIM

A new diclofenac effervescent tablet (DIC-BT) was developed in order to circumvent the high variable delay in delivery of the drug in enteric coated tablets of diclofenac (CAS 15307-86-5). The gastrointestinal side effects of the effervescent tablet were investigated in comparison to two other galenic principles of DIC preparations (DIC entero coated dragees = DIC-mrD) and dispersible tablets (DIC-DispT) and to acetylic salicylic acid (ASA (CAS 50-78-2). For the assessment of gastrointestinal side effects, two score systems were used simultaneously. The Lanza-scores were compared with our HEU-criteria system (Haemorrhage, Erosion, Ulceration) to find out if the pattern and the localisation of the lesions differ between the drugs tested.

METHODS

In a single-blind, randomised, controlled, parallel study design healthy volunteers (27 females, 33 males; mean age 26.9 years, mean b.w. 72.5 kg, Helicobacter pylori antibody negative) were treated by 150 mg/d DIC or 1500 mg ASA (as positive control group) for 7 days. DIC-BT (n = 20 subjects), DIC enteric coated dragees (DIC-mrD) (n = 20), DIC-Dispers tablets (DIC-DispT) (n = 10) and ASA (n = 10) were administered t.i.d. The effects were investigated by videoendoscopy with chromoscopy before and after treatment. Mucosa lesions were assessed according to the Lanza-scores and HEU-criteria system. The results were calculated as pre-post comparison and assessed as paired test between treatment groups.

RESULTS

DIC preparations caused mostly erosions and scarcely haemorrhages, but different from ASA only few combined lesions of haemorrhages and lesions in Corpus ventriculi and Bulbus duodeni. The number of mucosal lesions was different with regard to the region (Antrum ventriculi > Corpus ventriculi > Bulbus duodeni). The spreading with Helicobacter pylori (histological assessment at the end of study) varied between 20% and 50% (7/20 subjects in DIC-BT and DIC-msrD, respectively, 5/10 in DIC-dispT group, 2/10 subjects in the ASA group). Based on the HEU-criteria, erosions were seen in 9/20 subjects in DIC-BT, 10/20 subjects in DIC-mrD, 4/10 in DIC-DispT, and 3/10 subjects in ASA group, respectively, the combination of haemorrhages and erosions is seen in 2/20 subjects in DIC-BT, 6/20 in DIC-mrD, 4/10 subjects in DIC-DispT, and in 7/10 subjects in the ASA group, respectively. The difference is significantly between DIC-BT and ASA (p < 0.05) to the sum of all lesions in stomach. Based on Lanza-scores (score values > 2), (a) erosions were seen in 7/20 subjects in DIC-BT, 15/20 subjects in DIC-mrD, 7/10 in DIC-DispT, and 9/10 subjects in ASA group; (b) haemorrhages were seen in 0/20 subjects in DIC-BT, 5/20 subjects in DIC-mrD, 2/10 in DIC-DispT, and 4/10 subjects in ASA group, (c) combined type in 3/20 subjects in DIC-BT, 8/20 subjects in DIC-mrD, 5/10 in DIC-DispT, and 8/10 subjects in ASA group, respectively. Independent of the scoring systems, the difference was significant between DIC-BT and DIC-mrD, as well as between all DIC preparations and ASA. At the end of the study Helicobacter pylori infections were observed by biopsy in 20-50% of volunteers (DIC-BT and DIC-mrD in 7/20 subjects, each, and DIC-DispT in 5/10, and ASA in 2/10 subjects, respectively) and between Dic-BT and ASA (p < 0.05) for all categories.

CONCLUSION

Mucosal lesions induced by DIC-BT were significantly less than by DIC-mrD and DIC-DispT. The effect was confirmed by both scoring systems, i.e. Lanza scores and HEU-criteria system. Using the HEU-criteria the pattern and the localization of the lesions could be characterized. There were remarkable differences between the effects of DIC and ASA. The assessment of gastrointestinal side effects using the HEU-criteria was superior to Lanza-scores because there was no bias according to the type of lesion and the type of drug.

摘要

未标注

量化评分系统在判定上消化道黏膜变化中的应用/双氯芬酸泡腾片与传统双氯芬酸制剂及阿司匹林重复给药后的比较研究

背景与目的

为避免双氯芬酸(CAS 15307 - 86 - 5)肠溶片给药时药物递送高度可变的延迟,研发了一种新型双氯芬酸泡腾片(DIC - BT)。将该泡腾片与双氯芬酸制剂的另外两种剂型(双氯芬酸肠溶糖衣片 = DIC - mrD)和分散片(DIC - DispT)以及阿司匹林(ASA,CAS 50 - 78 - 2)相比较,研究其胃肠道副作用。为评估胃肠道副作用,同时使用了两种评分系统。比较兰扎评分与我们的HEU标准系统(出血、糜烂、溃疡),以查明受试药物之间病变的模式和定位是否存在差异。

方法

在一项单盲、随机、对照、平行研究设计中,健康志愿者(27名女性,33名男性;平均年龄26.9岁,平均体重72.5 kg,幽门螺杆菌抗体阴性)接受150 mg/d双氯芬酸或1500 mg ASA(作为阳性对照组)治疗7天。DIC - BT(n = 20名受试者)、双氯芬酸肠溶糖衣片(DIC - mrD)(n = 20)、双氯芬酸分散片(DIC - DispT)(n = 10)和ASA(n = 10)均每日给药3次。治疗前后通过染色内镜检查研究效果。根据兰扎评分和HEU标准系统评估黏膜病变。结果计算为治疗前后比较,并作为治疗组之间的配对检验进行评估。

结果

双氯芬酸制剂主要引起糜烂,很少引起出血,但与ASA不同,胃体和十二指肠球部仅有少量出血合并病变。黏膜病变数量在不同区域有所不同(胃窦>胃体>十二指肠球部)。幽门螺杆菌感染率(研究结束时的组织学评估)在20%至50%之间(DIC - BT和DIC - msrD组分别为7/20名受试者,DIC - dispT组为5/10,ASA组为2/10名受试者)。根据HEU标准,DIC - BT组9/20名受试者出现糜烂,DIC - mrD组10/20名受试者出现糜烂,DIC - DispT组4/10名受试者出现糜烂,ASA组3/10名受试者出现糜烂;DIC - BT组2/20名受试者出现出血合并糜烂,DIC - mrD组6/20名受试者出现出血合并糜烂,DIC - DispT组4/10名受试者出现出血合并糜烂,ASA组7/10名受试者出现出血合并糜烂。胃内所有病变总和方面,DIC - BT与ASA之间差异显著(p < 0.05)。根据兰扎评分(评分值>2),(a)DIC - BT组7/20名受试者出现糜烂,DIC - mrD组15/20名受试者出现糜烂,DIC - DispT组7/10名受试者出现糜烂,ASA组9/10名受试者出现糜烂;(b)DIC - BT组0/20名受试者出现出血,DIC - mrD组5/20名受试者出现出血,DIC - DispT组2/10名受试者出现出血,ASA组4/10名受试者出现出血;(c)DIC - BT组3/20名受试者出现复合型病变,DIC - mrD组8/20名受试者出现复合型病变,DIC - DispT组5/10名受试者出现复合型病变,ASA组8/10名受试者出现复合型病变。无论采用哪种评分系统,DIC - BT与DIC - mrD之间以及所有双氯芬酸制剂与ASA之间差异均显著。研究结束时,通过活检观察到20% - 50%的志愿者感染幽门螺杆菌(DIC - BT和DIC - mrD组各7/20名受试者,DIC - DispT组5/10名受试者,ASA组2/10名受试者),且所有类别中Dic - BT与ASA之间差异显著(p < 0.05)。

结论

DIC - BT引起的黏膜病变明显少于DIC - mrD和DIC - DispT。两种评分系统,即兰扎评分和HEU标准系统,均证实了这一效果。使用HEU标准可对病变的模式和定位进行特征描述。双氯芬酸与ASA的效果存在显著差异。使用HEU标准评估胃肠道副作用优于兰扎评分,因为该标准不受病变类型和药物类型的影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验